Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

China · Delayed Price · Currency is CNY

19.56

+0.15 (0.77%)

Jun 18, 2026, 3:00 PM CST

-8.64% (1Y)

Market Cap	7.89B -8.0%
Revenue (ttm)	1.68B +9.2%
Net Income	393.72M +0.4%
EPS	0.96 -2.8%
Shares Out	403.41M
PE Ratio	20.31
Forward PE	14.38
Dividend	0.34 (1.74%)
Ex-Dividend Date	Jun 15, 2026

Volume	2,607,000
Open	19.35
Previous Close	19.41
Day's Range	19.20 - 19.91
52-Week Range	18.09 - 35.58
Beta	-0.34
Analysts	Strong Buy
Price Target	28.00 (+43.15%)
Earnings Date	Aug 28, 2026

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides eplerenone, an API to treat cardiovascular diseases, lowering blood pressure, and treating heart failure; futicasone propionate, used for the treatment of asthma, respiratory tract diseases, and rhinitis; Teno... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1998

Employees 2,026

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 605116

Full Company Profile

Financial Performance

In 2025, Aurisco Pharmaceutical's revenue was 1.70 billion, an increase of 15.03% compared to the previous year's 1.48 billion. Earnings were 449.21 million, an increase of 26.61%.

Financial Statements